,2 Several common treatment regimens for patients with nonsquamous NSCLC combine a PD(L)1 inhibitor with maintenance pemetrexed for up to 2 years after completion of 4 cycles of induction platinum doublet plus PD(L)1 inhibitor.3, 4, 5, 6. The gene discussed is CD274; the disease is non-small cell lung carcinoma.